Home › Funds › Aisling Capital Management LP › BBOT

Aisling Capital Management LP position in BBOT

BRIDGEBIO ONCOLOGY THERAPEUT · Health Care

Aisling Capital Management LP reported holding 1,018,018 shares of BBOT (BRIDGEBIO ONCOLOGY THERAPEUT) in its Q3 2026 13F filing — a position valued at US$4.1M, representing 1.38% of its reported portfolio and ranking #7 among its reported holdings. Aisling Capital Management LP has disclosed BBOT holdings in 5 of the last 5 reported quarters, going back to Q3 2025.

Latest position (Q3 2026)1.02M sh
Reported value held$4.14M
Portfolio Weight1.38%
First reportedQ3 2025
Last changeHold
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Aisling Capital Management LP's BBOT position evolved

Aisling Capital Management LP first disclosed a stake in BBOT in Q3 2025 at 564,625 shares (US$6.5M). The position peaked in Q1 2026 at 1,018,018 shares, worth US$9.1M. Across 5 filings, Aisling Capital Management LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 3 time(s). The most recent filing (Q3 2026) shows 1,018,018 shares valued at US$4.1M. Notable position changes include a 80% increase in Q1 2026 (shares fell 15% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2025 564.62K $6.54M New
Q4 2025 564.62K $7.07M Hold
Q1 2026 1.02M $9.11M Add
Q2 2026 1.02M $7.76M Hold
Q3 2026 1.02M $4.14M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BBOT and 13F data

BBOT (BRIDGEBIO ONCOLOGY THERAPEUT) is a Health Care company. 81 other funds we track also report a position in BBOT — the largest reported positions include Cormorant Asset Management, LP (US$136.2M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$37.2M), Omega Fund Management, LLC (US$25.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BBOT

All BBOT fund holders →

FAQ

How long has Aisling Capital Management LP held BBOT?

Aisling Capital Management LP has disclosed BBOT holdings in 5 of the last 5 reported quarters, going back to Q3 2025.

What is Aisling Capital Management LP's current position in BBOT?

As of Q3 2026, Aisling Capital Management LP holds 1.02M shares of BBOT (BRIDGEBIO ONCOLOGY THERAPEUT), valued at $4.14M, representing 1.38% of its reported portfolio and ranking #7.

Has Aisling Capital Management LP been buying or selling BBOT?

In the latest 13F filing (Q3 2026), Aisling Capital Management LP held unchanged its position in BBOT. The position peaked in Q1 2026 at 1.02M shares.

Which other funds hold BBOT?

Other major institutional holders of BBOT include Cormorant Asset Management, LP, DEERFIELD MANAGEMENT COMPANY, L.P., Omega Fund Management, LLC, among 81 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.